Floatz logo

Fenofibrate

Central Nervous System Tumor, Pediatric

Dana-Farber Cancer InstituteSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Central Nervous System Tumor, Pediatric cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Dana-Farber Cancer Institute
Phase 2B
Thalidomide
Dana-Farber Cancer Institute
Phase 2B
Cyclophosphamide
Dana-Farber Cancer Institute
Phase 2B
Dfn-15
Dana-Farber Cancer Institute
Phase 2B

Same molecule, other indications

Fenofibrate is also rated in:

inherited lipid metabolism disorderDormant
BBB
Indicative ·
74 / 100
View asset →
primary biliary cholangitisDormant
BB
Indicative ·
71 / 100
View asset →
hypertriglyceridemiaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →